OTC : MAYNF

Mayne Pharma Group Limited

$2 USD

$0.1 (5.26%)

Volume
6.1K
Average Volume
295
Market Capitalization
$162.49M
P/E Ratio
-2.74
Dividend Yield
0.00%
Price Target
Year High
$4.00
Year Low
$1.40
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$1.33
Company Overview

OTC

Aaron Gray

Drug Manufacturers - General

Healthcare

MAYNF

491

AU

USD

https://www.maynepharma.com

61 8 8209 2666

N/A

N/A

Liquidity Metrics

0.13

1.33

1.14

0.26

0.00

Sales & Valuation

$408.1M

0.58

0.67

15.14

0.19

Profitability

-$1.14

-$93.84M

-20.44%

-15.48%

-23.02%

-8.85%

P/E Metrics

-2.74

-0.10

-0.10

Analyst Price Target & Rating

Sell

2/5

0 Analysts

%

Financial Health Scores

-0.55

5/9

$83.71M

$940.18M

$587.61M

-$56.78M

Key Metrics (TTM)

$193.38M

0.48

8.27

1.33

-23.02%

-6.28%

-38.51%

7.27%

221 days

Company Executives
Name Title
Thomas Duthy Manager of Investor Relations
Tony Ramy Executive Vice President of Women's Health
Brenton Walter Financial Controller
Daniel Moore President of DistributeRx
Kurt Reyes Interim Global Head of People & Culture
Aaron Gray Chief Executive Officer
Frank Casty Executive VP, Global Head of R&D and Chief Medical Officer
Kimberly Parker Executive Vice President & General Counsel
Laura Loftus Associate General Counsel & Company Secretary
Brant Schofield Executive Vice President of Corporate Development
Poll Results

No votes yet today — be the first to share your view!

About Mayne Pharma Group Limited (OTC:MAYNF) Stock

Mayne Pharma Group Limited is an Australian-headquartered specialty pharmaceutical enterprise, engaged in the development, production, and marketing of both patented (branded) and generic drug formulations. Its commercial reach spans Australia, New Zealand, North America (covering the United States and Canada), Europe, and Asia. The company's operations are divided into four main segments: Metrics Contract Services, International, Branded Products, and Portfolio Products. Beyond its own product lines, Mayne Pharma offers sophisticated oral drug delivery technologies and comprehensive contract services—including pharmaceutical development, manufacturing, and analytical testing—to other businesses. Its strategic focus areas for specialty product distribution include dermatology, women's heal ... th, and infectious disease treatments. Originally established in 2005, the company operated under the name Halcygen Pharmaceuticals Limited before rebranding to Mayne Pharma Group Limited in November 2010. Its principal office is located in Salisbury South, Australia.

Frequently Asked Questions

What is the current Mayne Pharma Group Limited (MAYNF) stock price?

Mayne Pharma Group Limited(OTC:MAYNF) stock price is $2 in the last trading session. During the trading session, MAYNF stock reached the peak price of $4 while $1.4 was the lowest point it dropped to. The percentage change in MAYNF stock occurred in the recent session was 5.26% while the dollar amount for the price change in MAYNF stock was $0.1.

MAYNF's industry and sector of operation?

The OTC listed MAYNF is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector.

Who are the executives of MAYNF?

Thomas Duthy | Manager of Investor Relations
Tony Ramy | Executive Vice President of Women's Health
Brenton Walter | Financial Controller
Daniel Moore | President of DistributeRx
Kurt Reyes | Interim Global Head of People & Culture

How many employees does MAYNF have?

Number of MAYNF employees currently stands at 491. MAYNF operates from 1538 Main North Road, Salisbury South, SA 5106, AU.

Link for MAYNF official website?

Official Website of MAYNF is: https://www.maynepharma.com

How do I contact MAYNF?

MAYNF could be contacted at phone #61 8 8209 2666 and can also be accessed through its website. MAYNF operates from 1538 Main North Road, Salisbury South, SA 5106, AU.

How many shares of MAYNF are traded daily?

The average number of MAYNF shares traded daily for last 3 months was 295.

What is the market cap of MAYNF currently?

The market value of MAYNF currently stands at $162.49M with its latest stock price at $2